Welcome to this week's digest. For April 13 to April 19, 2026, the focus is on regulatory evolution: FDA issues new NGS safety guidance for genome editing, radioligand theranostics advance in brain metastases, and expert signals highlight pediatric CGT trial design challenges alongside radioligand therapy's projected mainstream expansion.
🤖 Artificial Intelligence
No major verified update this week
No significant AI developments in drug discovery or clinical development were reported this week.
🧬 Gene Therapy
FDA issues draft NGS-based safety guidance for genome editing gene therapy products
The draft "Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing" provides detailed recommendations on sequencing strategies, sample selection, analysis parameters, and reporting to characterize off-target activity and genome integrity for both ex vivo and in vivo genome-editing products.
Why it matters: This guidance is intended to support nonclinical packages in INDs and BLAs, including bespoke ultra-rare programs, and builds on FDA's earlier 2024 genome-editing guidance and its new bespoke-therapy framework to standardize safety expectations while enabling faster development of individualized therapies.
Uncertainty note: The source URL in the provided digest appears truncated.
Source: U.S. Food and Drug Administration draft guidance and accompanying coverage in BioSpace →☢️ Radioligand Theranostics
Radiopharm Theranostics completes U.S. Phase 2b enrollment for FASN-targeted PET tracer RAD101 in recurrent brain metastases
Radiopharm has dosed the final patient in its U.S. multicenter, open-label Phase 2b trial of 18F-RAD101 in 30 individuals with recurrent brain metastases from solid tumors, with interim data demonstrating approximately 90% concordance between RAD101 PET and gadolinium-enhanced MRI for lesion detection, the study's primary endpoint.
Why it matters: RAD101, a fatty acid synthase-targeted PET radiopharmaceutical with FDA Fast Track designation, is expected to deliver primary-endpoint data in June 2026 and then advance into a U.S. Phase 3 pivotal trial, moving a novel imaging agent for brain metastases closer to potential registration in a high-unmet-need CNS setting.
Uncertainty note: The source URL in the provided digest appears truncated.
Source: Radiopharm Theranostics press release and associated Form 6-K summary →📡 Expert Signals
FDA CBER Office of Therapeutic Products & Alliance for Regenerative Medicine
At an April 9 hybrid workshop on "Advancing Pediatric Cell and Gene Therapy Clinical Trials," FDA and ARM highlighted the need to tailor pediatric CGT trial designs toward earlier intervention while addressing long-term safety follow-up, ethical constraints, and operational feasibility in ultra-rare diseases.
Uncertainty note: The source URL in the provided digest appears truncated.
Source: FDA workshop link as provided in digest →Center for Security and Emerging Technology (CSET), Georgetown University
CSET's analysis of the White House National Policy Framework for AI stresses that the administration's core goal is federal preemption of divergent state AI laws, using a single national framework that prioritizes innovation and existing sector regulators (e.g., FDA) rather than a new standalone AI agency.
Uncertainty note: The source URL in the provided digest appears truncated.
Source: CSET Georgetown analysis →Clinicians and policymakers at a national radioligand therapy summit (Belgium), reported by Medscape
Experts at a national summit projected that radioligand therapy could expand the pool of eligible oncology patients by a factor of 10–15 by 2035 and urged its explicit incorporation into national cancer plans, reflecting expectations that RLT will become a mainstream modality rather than a niche salvage option.
Uncertainty note: The source URL in the provided digest appears truncated.
Source: Medscape coverage →📰 In Case You Missed It
White House National Policy Framework for Artificial Intelligence (released March 20, 2026)
Outlining legislative recommendations for a unified federal AI policy, including targeted preemption of certain state AI laws and reliance on existing federal agencies for sector-specific oversight.
Why still relevant: This framework is shaping congressional debate on U.S. AI legislation and will influence how future federal rules treat healthcare, life-sciences, and clinical AI tools, including possible limits on state-level experimentation that might otherwise impose divergent requirements on AI used in trials and care delivery.
Uncertainty note: The source URL in the provided digest appears truncated.
Source: HK Law coverage →FDA's first draft guidance on the use of artificial intelligence in drug and biologic development (January 2026)
Proposes a risk-based framework emphasizing clearly defined context-of-use, systematic AI risk assessment, and evidence that AI outputs are reliable for their intended regulatory purpose.
Why still relevant: Sponsors using AI for modeling, dose selection, response prediction, data cleaning, or decision-support in development are now expected to map these use cases to the draft framework, which is already informing FDA review expectations for AI-described in INDs and BLAs.
Uncertainty note: The source URL in the provided digest appears truncated.
Source: IMO Health coverage →FDA's January 11, 2026 reforms to CMC expectations for cell and gene therapies
Described in paired news releases on increased flexibility and "Flexible Requirements for Cell and Gene Therapies to Advance Innovation."
Why still relevant: The updated CMC posture—such as reduced prescriptive requirements around process-validation lots for certain CGTs—directly affects manufacturing strategy, comparability, and BLA-readiness for gene therapy programs moving into pivotal studies over 2026–2027.
Uncertainty note: The source URL in the provided digest appears truncated.
Source: Goodwin Law coverage →Phase 1b/2 PRINCE trial of multicycle [177Lu]Lu-PSMA-617 plus pembrolizumab in metastatic castration-resistant prostate cancer
Published in The Lancet Oncology with lay coverage on April 5, 2026.
Why still relevant: The trial showed PSA50 responses in 76% of heavily pretreated patients and a manageable safety profile, supporting further exploration of radioligand–checkpoint inhibitor combinations and informing design assumptions for future randomized studies and sequencing in advanced prostate cancer.
Uncertainty note: The source URL in the provided digest appears truncated.
Source: CancerNetwork coverage →Radiopharm Theranostics–Siemens Healthineers clinical supply agreement for 18F-RAD101 in the United States (announced April 7, 2026)
The deal secures manufacturing and distribution capacity ahead of a planned U.S. Phase 3 registrational trial in brain metastases.
Why still relevant: This reduces supply-chain risk for a first-in-class FASN-targeted imaging agent and signals serious intent to take RAD101 through to registration.
Uncertainty note: The source URL in the provided digest appears truncated.
Source: Yahoo Finance coverage →🎯 Practical Implications
For genome-editing programs, align NGS-based off-target and structural-variant assessment strategies with the new FDA draft guidance
Include its expectations on sequencing design, sample selection, analysis parameters, and reporting in support of IND/BLA submissions.
Revisit CMC plans for cell and gene therapies
Including process-validation strategy, lot-release design, and lifecycle management—to leverage FDA's more flexible CGT CMC posture while still generating robust control of critical quality attributes.
When embedding AI/ML into drug and biologic development, ensure each use case is explicitly documented
Include context-of-use, risk characterization, and validation plans that are traceable to FDA's emerging AI-in-drug-development framework.
For pediatric CGT portfolios, pressure-test trial designs against themes from the recent FDA–ARM workshop
Consider earlier intervention, long-term follow-up burden, consent/assent, and feasibility in ultra-rare conditions before locking pivotal strategies or engaging with regulators.
In theranostics, plan operational capability with an eye to near-term readouts and scaling needs
Focus on PSMA-targeted therapies and emerging agents such as RAD101, as data and supply agreements signal intent to move these assets into mainstream oncology pathways rather than late-line niches.